1. Home
  2. CBIO vs BIOX Comparison

CBIO vs BIOX Comparison

Compare CBIO & BIOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CBIO
  • BIOX
  • Stock Information
  • Founded
  • CBIO 2003
  • BIOX 2001
  • Country
  • CBIO United States
  • BIOX Argentina
  • Employees
  • CBIO N/A
  • BIOX N/A
  • Industry
  • CBIO
  • BIOX Agricultural Chemicals
  • Sector
  • CBIO
  • BIOX Industrials
  • Exchange
  • CBIO Nasdaq
  • BIOX Nasdaq
  • Market Cap
  • CBIO 308.0M
  • BIOX 168.3M
  • IPO Year
  • CBIO N/A
  • BIOX N/A
  • Fundamental
  • Price
  • CBIO $14.29
  • BIOX $2.77
  • Analyst Decision
  • CBIO Strong Buy
  • BIOX Strong Buy
  • Analyst Count
  • CBIO 5
  • BIOX 4
  • Target Price
  • CBIO $25.60
  • BIOX $8.38
  • AVG Volume (30 Days)
  • CBIO 98.3K
  • BIOX 279.5K
  • Earning Date
  • CBIO 07-31-2025
  • BIOX 09-08-2025
  • Dividend Yield
  • CBIO N/A
  • BIOX N/A
  • EPS Growth
  • CBIO N/A
  • BIOX N/A
  • EPS
  • CBIO N/A
  • BIOX N/A
  • Revenue
  • CBIO N/A
  • BIOX $383,289,394.00
  • Revenue This Year
  • CBIO N/A
  • BIOX N/A
  • Revenue Next Year
  • CBIO N/A
  • BIOX $7.30
  • P/E Ratio
  • CBIO N/A
  • BIOX N/A
  • Revenue Growth
  • CBIO N/A
  • BIOX N/A
  • 52 Week Low
  • CBIO $10.83
  • BIOX $2.60
  • 52 Week High
  • CBIO $21.40
  • BIOX $11.39
  • Technical
  • Relative Strength Index (RSI)
  • CBIO 52.92
  • BIOX 35.91
  • Support Level
  • CBIO $13.50
  • BIOX $2.63
  • Resistance Level
  • CBIO $16.00
  • BIOX $2.89
  • Average True Range (ATR)
  • CBIO 0.79
  • BIOX 0.19
  • MACD
  • CBIO 0.16
  • BIOX 0.02
  • Stochastic Oscillator
  • CBIO 39.68
  • BIOX 30.77

About CBIO Crescent Biopharma Inc. Common Stock

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

About BIOX Bioceres Crop Solutions Corp.

Bioceres Crop Solutions Corp is a fully integrated provider of crop productivity solutions, including seeds, seed traits, seed treatments, biologicals, high-value adjuvants, and fertilizers. The company has developed a multi-discipline and multi-product platform capable of providing solutions throughout the entire crop cycle, from pre-planting to transportation and storage. Some of the products offered by the company include fertilizers, inoculants, adjuvants, crop protection solutions, and seeds among others. Its operating segments are crop protection, which derives key revenue, seed and integrated products, and crop nutrition. Geographically, the majority of the company's revenue is generated from Argentina and the rest from Brazil, North America, Latin America, and other regions.

Share on Social Networks: